Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis

2020494 citationsJournal Articlebronze Open Access

Authors

Franco Locatelli · Bambino Gesù Children's Hospital

Michael B. Jordan · Bambino Gesù Children's Hospital

Carl E. Allen · Baylor College of Medicine

Simone Cesaro · Azienda Ospedaliera Universitaria Integrata Verona

Carmelo Rizzari · Bambino Gesù Children's Hospital

Anupama Rao · Great Ormond Street Hospital

Barbara Degar

Abstract

Emapalumab was an efficacious targeted therapy for patients with primary hemophagocytic lymphohistiocytosis. (Funded by NovImmune and the European Commission; NI-0501-04 and NI-0501-05 ClinicalTrials.gov numbers, NCT01818492 and NCT02069899.).

Topics & Keywords

Autoimmune and Inflammatory Disorders Research Immune Cell Function and Interaction Family and Disability Support Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 382, Issue 19, pp. 1811-1822

DOI: 10.1056/nejmoa1911326

Field-Weighted Citation Impact: 38.92